A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

Clinical trial NCT06563804 · TERMINATED

Trial details

NCT number: NCT06563804
Sponsor: Servier Bio-Innovation LLC
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)/AML Chronic Myelomonocytic Leukemia (CMML)

Start date: 2025-02-25
Primary completion: 2025-10-09
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.